Drug Type Antibody fusion proteins |
Synonyms |
Target |
Action inhibitors |
Mechanism MAGEA3 inhibitors(Melanoma-associated antigen 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Preclinical | China | 27 May 2024 | |
Esophageal Carcinoma | Preclinical | China | 27 May 2024 | |
Liver Cancer | Preclinical | China | 27 May 2024 |